UTHR (United Therapeutics) Institutional Ownership: 108.11% (As of Jul. 11, 2026)


UTHR United Therapeutics Corp UTHR
88 GF Score
Price $547.06
GF Value $387.00
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Institutional Ownership?

United Therapeutics UTHR -0.98% 88 Institutional Ownership is 108.11% as of Jul. 11, 2026. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $387.00 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, United Therapeutics's institutional ownership is 108.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, United Therapeutics's Insider Ownership is 0.40%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, United Therapeutics's Float Percentage Of Total Shares Outstanding is 85.48%.

United Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Institutional Ownership Chart

United Therapeutics Historical Data

The historical data trend for United Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 58.54 59.11 59.56 58.59 58.25 58.56 60.17 58.93 59.16 58.41
UTHR
88GF Score
United Therapeutics Corp UTHR
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 108.11% mean?
United Therapeutics (UTHR) has a Institutional Ownership of 108.11% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' Institutional Ownership too high?
United Therapeutics' current Institutional Ownership is 108.11%. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Institutional Ownership compare to VTRS and NBIX?
United Therapeutics' Institutional Ownership of 108.11% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on United Therapeutics and its competitors. United Therapeutics's current Institutional Ownership is 108.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $387.00, compared to a current price of $547.06 — trading 41.4% above its estimated fair value. The current Institutional Ownership is 108.11%. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Institutional Ownership is 108.11% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $547.06 is trading 41.4% above its estimated GF Value™ of $387.00. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

  • Institutional Ownership: 108.11%
  • GF Value™: $387.00 vs. price of $547.06 (41.4% above fair value)
  • GF Score™: 88/100 with 7 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score

Get the complete analysis for UTHR

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$547.06
Price
$387.00
GF Value